These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 5072392)

  • 1. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
    Pfeiffer R; Ebadi M
    J Neurochem; 1972 Sep; 19(9):2175-81. PubMed ID: 5072392
    [No Abstract]   [Full Text] [Related]  

  • 2. L-Dopa and pyridoxine.
    Tran N
    Lancet; 1972 Jul; 2(7766):45-6. PubMed ID: 4113642
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 4. How does L-dopa work in parkinsonism?
    Sandler M
    Lancet; 1971 Apr; 1(7703):784. PubMed ID: 4101278
    [No Abstract]   [Full Text] [Related]  

  • 5. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V
    Arch Neurol; 1973 Feb; 28(2):107-10. PubMed ID: 4683147
    [No Abstract]   [Full Text] [Related]  

  • 6. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
    Seiden LS; Martin TW
    Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa.
    Airoldi L; Watkins CJ; Wiggins JF; Wurtman RJ
    Metabolism; 1978 Jul; 27(7):771-9. PubMed ID: 661563
    [No Abstract]   [Full Text] [Related]  

  • 9. Passage into the rat brain of dopa and dopamine injected into the lateral ventricle.
    Constantinidis J; Gaillard JM; Geissbuhler F; Tissot R
    Br J Pharmacol; 1971 Sep; 43(1):32-8. PubMed ID: 5136462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats.
    Kuruma I; Bartholini G; Tissot R; Fletscher A
    J Pharm Pharmacol; 1972 Apr; 24(4):289-94. PubMed ID: 4402836
    [No Abstract]   [Full Text] [Related]  

  • 11. Pyridoxine reversal of L-dopa effects in Parkinsonism.
    Duvoisin RC; Yahr MD; Coté LD
    Trans Am Neurol Assoc; 1969; 94():81-4. PubMed ID: 5374494
    [No Abstract]   [Full Text] [Related]  

  • 12. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 13. L-Dopa and imipramine: biochemical and behavioral interaction.
    Friedman E; Gershon S
    Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

  • 16. Pyridoxine, DOPA, and Parkinsonism.
    Yahr MD; Duvoisin RC; Côté L; Cohen G
    Adv Biochem Psychopharmacol; 1972; 4():185-94. PubMed ID: 4555927
    [No Abstract]   [Full Text] [Related]  

  • 17. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).
    Hornykiewicz O
    Br Med Bull; 1973 May; 29(2):172-8. PubMed ID: 4356552
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.